Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Soon after WADA took action, the FDA added BPC-157 to the so-called Category 2 Bulk Substance List, which designates it as not eligible for compounding for human use
Obsessive disorders (Obsessive Compulsive Disorder, OCD) also respond to SSRIs, suggesting a similar mechanism
Ends Soon
[1] In neurological models, BPC-157 has been tested against dopamine-depleting lesions, traumatic brain injury, and spinal cord compression
The practical advice is straightforward
Patients with Pernicious Anaemia, and their families, were unable to reconcile this latest advice with the information that they were given at diagnosis that their treatment would be a life-saving injection every month, every two months or at the least every three months
